Comparative Pharmacology
Head-to-head clinical analysis: CROMOLYN SODIUM versus NEDOCROMIL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOLYN SODIUM versus NEDOCROMIL SODIUM.
CROMOLYN SODIUM vs NEDOCROMIL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
Nedocromil sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells and other inflammatory cells. It also reduces sensory nerve activation and inhibits eosinophil chemotaxis.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
2 inhalations (2 mg per inhalation) four times daily via metered-dose inhaler, or 2 inhalations (4 mg per inhalation) twice daily via dry powder inhaler.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Terminal elimination half-life is approximately 2 hours; clinically, this supports twice-daily dosing for sustained effect.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Primarily renal excretion of unchanged drug; approximately 70% excreted in urine and 30% in feces via biliary elimination.
Category A/B
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer